CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
Genetic counseling, testing and family communication into survivorship after diagnosis of breast cancer
-
9-10-
-
-
Source: J Clin Oncol. 42(26):3123-3129
Details:
-
Alternative Title:J Clin Oncol
-
Personal Author:
-
Description:Purpose:
To examine receipt of genetic testing and communication with relatives about results into survivorship after diagnosis of breast cancer.
Patients and methods:
Women aged 20–79 diagnosed with early-stage breast cancer in 2014–2015 and reported to the Georgia and Los Angeles County SEER registries were surveyed approximately seven months and six years after diagnosis (N=1412). We asked about genetic counseling, testing, and communication with relatives about results. We categorized women into indications for testing based on clinical guidelines at time of diagnosis and at the time of the follow-up survey.
Results:
47.4% had indications for genetic testing at any time: 28.0% at baseline and an additional 19.4% at time of the follow-up survey (FUPs only); 71.9% (95% CI 67.4%−76.4%) of those with a baseline indication reported genetic testing vs. 53.3% (95% CI 47.3% - 59.2%) with an indication at FUPs only and 35.0% (95% CI 31.6% - 38.4%) with no indication (p<.001). There were no significant racial or ethnic differences in receipt of testing, controlling for age and clinical indications (p=0.239); results for genetic counseling were similar. Only 3.4% of survivors had direct-to-consumer testing (DTCt) for cancer. Testers who reported a pathogenic variant (n=62) were much more likely to have talked to most or all their first-degree adult relatives about genetic testing than those with a variant of unknown significance (n=49) or a negative finding (n=419): 62.7% vs 38.8% and 38.0%, respectively (p<.001).
Conclusion:
Many women with indications for genetic counseling and testing into survivorship do not receive it. But those tested reach out to family members based on the clinical relevance of their results. Very few patients obtained DTCt, which suggests that these tests do not substitute for clinical testing in breast cancer survivors.
-
Subjects:
-
Source:
-
Pubmed ID:39008790
-
Pubmed Central ID:PMC11377164
-
Document Type:
-
Funding:
-
Volume:42
-
Issue:26
-
Collection(s):
-
Main Document Checksum:
-
File Type:
-
Supporting Files:No Additional Files
